Nucleic acid combination product for detecting bladder cancer or urothelium cancer and application of nucleic acid combination product

By detecting the methylation status of TWIST1, PENK and NID2 genes, the problem of insufficient sensitivity and specificity in the diagnosis of bladder and urothelial cancer is solved, providing an efficient non-invasive diagnosis method, and improving the accuracy of early diagnosis and prognosis of patients.

CN118932057AActive Publication Date: 2024-11-12INTELLINOSIS BIOTECHNOLOGY (SHANGHAI) CO LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202411038407.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-03-20
Filing Date
2024-07-31
Publication Date
2024-11-12
Estimated Expiration
2044-07-31

AI Technical Summary

Technical Problem

The existing diagnostic methods for bladder and urothelial cancer have insufficient sensitivity and specificity, which cannot effectively improve the early diagnosis rate, and routine examinations have problems such as high invasiveness, high cost, missed diagnosis rate and misdiagnosis rate.

Method used

Provide a nucleic acid combination product, including primer pairs and probes for detecting TWIST1, PENK and NID2 genes, to detect methylation status in urine by methylation-specific real-time fluorescence PCR, for bladder cancer and urothelial The diagnosis of cancer improves the sensitivity and specificity of diagnosis.

Benefits of technology

It has achieved high sensitivity and specific diagnosis of bladder cancer and urothelial cancer, reduced the rate of missed diagnosis and misdiagnosis, provided a non-invasive and convenient early diagnosis method, and improved patient compliance and quality of life.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118932057A_ABST
    Figure CN118932057A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biomedicine, in particular to a nucleic acid combination product for detecting bladder cancer or urothelial carcinoma and application of the nucleic acid combination product. According to the nucleic acid combination product, on the basis of detecting the primer pair and the probe of the single TWIST1 gene, the primer pair and the probe for detecting at least one of the two auxiliary genes NID2 and PENK are added, the positive detection rate and accuracy of bladder cancer and urothelial carcinoma are improved, and more possibilities are provided for early discovery and treatment of tumor diseases.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims priority to Chinese patent application No. 2024103225640 filed on March 20, 2024, with invention name “Nucleic acid combination product for detecting bladder cancer and its application”, the entire contents of which are incorporated by reference into this application. Technical Field

[0002] The present application relates to the field of biomedical technology, and in particular to a nucleic acid combination product for detecting bladder cancer or urothelial cancer and its application. Background Art

[0003] Bladder cancer (BC) is the 10th most common cancer worldwide, with approximately 570,000 new cases and more than 210,000 deaths each year. Clinically, routine bladder cancer examinations include urine routine, B-ultrasound, urine exfoliative cytology, and cystoendoscopy FISH. Cystoscopy may lead to risks such as urinary tract infection, urethral injury, and bladder injury. Ordinary cystoscopy leads to poor patient compliance, while painless cystoscopy has anesthesia risks, high fees, and cannot avoid the risk of urinary tract infection. B-ultrasound and urine exfoliative cytology examination methods are not sensitive or specific, and cannot accurately identify patients, especially those in the early stages of cancer.

[0004] Traditional early screening methods have many limitations. If we want to effectively improve the early diagnosis rate of bladder cancer, new technologies are needed to break the ice. Liquid biopsy is a highly anticipated cancer early diagnosis technology in recent years. It is a genetic testing method that uses non-invasive methods to collect DNA from human body fluids to diagnose tumors. The main biomarkers include circulating tumor cells (CTC), ctDNA and exosomes. For example, by detecting the gene methylation status of tumor cells shed in urine, it can assist in the evaluation of the occurrence, recurrence, and efficacy of medication of bladder cancer.

[0005] Multiple factors are associated with the recurrence and progression of bladder cancer and affect patient survival. Currently, there are many molecular markers used to examine bladder cancer, but their value is very limited. Therefore, new molecular markers are needed to detect bladder cancer patients (especially those with a high risk of progression and recurrence). Recently, epigenetic markers can be used as an assessment of the high risk of progression to cancer, providing new opportunities for treatment and prevention. DNA methylation as a biomarker has received increasing attention in recent years because abnormal DNA methylation is a major feature of bladder cancer and plays a key role in the occurrence and progression of bladder cancer.

[0006] Genetics studies genetic information based on genes, while epigenetics studies reversible changes in heritable gene function and other cellular phenotypes that occur without any DNA changes. DNA methylation occurs throughout the genome, including the addition of a methyl group to the cytosine ring of CpG dinucleotides by methyltransferases. DNA methylation is a key regulator of gene transcription and genome stability. In human cancers, abnormal changes in DNA methylation patterns, high expression of activated oncogenes and silencing of tumor suppressor genes, cause a loss of balance between carcinogenesis and tumor suppression, and ultimately lead to the occurrence of cancer. Many cancers show low methylation throughout the genome, and the promoter regions of certain genes (proven to be tumor suppressor genes) are highly methylated, which makes it possible to use methylation as a marker for cancer. In addition, each tumor type may have its own unique methylation pattern, which allows the development of various tumor-specific methylation markers. Changes in epigenetic events occur at the stage of carcinogenesis or in the early stages of cancer, so gene methylation as a molecular diagnosis may help detect cancer before symptoms or obvious imaging manifestations appear.

[0007] Great progress has been made in epigenetic research on bladder cancer. Since hypermethylation of tumor suppressor gene promoters is common in bladder cancer, potential DNA methylation markers have been identified in serum, bladder washing fluid, urine samples and cancer tissues. Therefore, DNA methylation can be used as a biological marker for early detection, effective treatment and accurate prognosis of bladder cancer.

[0008] A single-center study used MS-qPCR to detect four methylation sites (VIM, RASSF1A, GDF15, and TMEFF2) to diagnose bladder cancer, with a sensitivity of 82% and a specificity of 53%. Previous research results have shown that DNA methylation in urine is an effective marker for diagnosing bladder cancer, but its sensitivity and specificity still need to be improved.

[0009] Recently, the Huang Jian / Lin Tianxin team published a research report titled "Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer" in the Journal of Clinical Investigation, written by Chen Xu. The study identified 26 bladder cancer-specific methylation sites by integrating and analyzing the bladder cancer sequencing data of three cohorts, and then modeled and verified two methylation sites using a single-center cohort of 313 cases and a prospective multicenter cohort of 175 cases. The AUC of the training group and the validation group were 0.919 and 0.903, respectively. The overall accuracy for bladder cancer patients was 86.7%, the sensitivity was 90.0%, and the specificity was 83.1%.

[0010] Overall, the current non-invasive urine biomarker detection methods for bladder cancer are not ideal in terms of sensitivity or specificity, with high rates of missed diagnosis and misdiagnosis, which are difficult to meet clinical needs and have a very low actual clinical application rate.

[0011] Urothelial carcinoma (UC) is a common malignant tumor worldwide. Early diagnosis is crucial for the prognosis of patients with UC, because the five-year survival rate of patients with localized UC can exceed 90%, while once muscle invasion or metastasis occurs, the patient's survival and quality of life will be significantly reduced.

[0012] Currently, the diagnostic methods for urothelial carcinoma include cystoscopy, urine exfoliated cytology, fluorescence in situ hybridization (FISH), etc., but these methods have certain limitations. For example, cystoscopy combined with biopsy, as the "gold standard" for the diagnosis of urothelial carcinoma, although highly accurate, is not suitable for large-scale screening due to its high invasiveness and high price. Therefore, researchers are looking for more convenient, non-invasive, sensitive and specific early diagnosis methods.

[0013] In recent years, urine DNA testing has shown great potential as a non-invasive detection method. By detecting DNA copy number variations and methylation variations in urine, tumors and normal tissues can be accurately predicted. The team of Professor He Zhisong of the First Affiliated Hospital of Peking University and the team of Professor Ye Dingwei of Shanghai Fudan Cancer Hospital, in collaboration with Golden Oak Medical, published data on the world's first urine early screening and efficacy monitoring product for urothelial carcinoma, meeting the needs of more accurate, convenient and non-invasive diagnosis and treatment pathways for urothelial carcinoma. In addition, the Urothelial Carcinoma Expert Committee of the Chinese Society of Clinical Oncology (CSCO) issued the "Guidelines for the Diagnosis and Treatment of Urothelial Carcinoma (2020 Edition)", which provides an important reference for the diagnosis and treatment of urothelial carcinoma in China, including guidance for early diagnosis.

[0014] In general, the research background of early diagnosis of urothelial carcinoma focuses on improving diagnostic accuracy, reducing invasiveness, and increasing patient compliance, while emphasizing the combination of domestic and foreign research results and China's actual clinical situation in order to improve patients' prognosis and quality of life.

[0015] In view of this, this application is hereby filed. Summary of the invention

[0016] One or more embodiments of the present application provide a nucleic acid combination product for detecting bladder cancer or urothelial carcinoma and its application. The nucleic acid combination product can be used for the diagnosis of bladder cancer and urothelial carcinoma with good specificity and high sensitivity.

[0017] One or more embodiments of the present application provide a nucleic acid combination product, which includes a primer pair and a probe for detecting a biomarker;

[0018] The primer pairs and probes for detecting biomarkers include: primer pairs and probes for detecting TWIST1 gene, and primer pairs and probes for detecting one or more of PENK gene and NID2 gene;

[0019] The primer pair and probe for detecting the TWIST1 gene include: a forward primer shown in any one of SEQ ID NO.1, SEQ ID NO.4, SEQ ID NO.7, SEQ ID NO.10 and SEQ ID NO.13, a reverse primer shown in any one of SEQ ID NO.2, SEQ ID NO.5, SEQ ID NO.8, SEQ ID NO.11 and SEQ ID NO.14, and a probe shown in any one of SEQ ID NO.3, SEQ ID NO.6, SEQ ID NO.9, SEQ ID NO.12 and SEQ ID NO.15;

[0020] The primer pair and probe for detecting the PENK gene include: a forward primer shown in any one of SEQ ID NO.16, SEQ ID NO.19, SEQ ID NO.22, SEQ ID NO.25 and SEQ ID NO.28, a reverse primer shown in any one of SEQ ID NO.17, SEQ ID NO.20, SEQ ID NO.23, SEQ ID NO.26 and SEQ ID NO.29, and a probe shown in any one of SEQ ID NO.18, SEQ ID NO.21, SEQ ID NO.24, SEQ ID NO.27 and SEQ ID NO.30;

[0021] The primer pair and probe for detecting the NID2 gene include: a forward primer shown in any one of SEQ ID NO.31 and SEQ ID NO.34, a reverse primer shown in any one of SEQ ID NO.32 and SEQ ID NO.35, and a probe shown in any one of SEQ ID NO.33 and SEQ ID NO.36.

[0022] In some embodiments of the present application, the primer pair and probe for detecting the TWIST1 gene include:

[0023] The forward primer shown in SEQ ID NO.1, the reverse primer shown in SEQ ID NO.2, and the probe shown in SEQ ID NO.3; or,

[0024] The forward primer shown in SEQ ID NO.4, the reverse primer shown in SEQ ID NO.5, and the probe shown in SEQ ID NO.6; or, the forward primer shown in SEQ ID NO.7, the reverse primer shown in SEQ ID NO.8, and the probe shown in SEQ ID NO.9; or,

[0025] The forward primer shown in SEQ ID NO.10, the reverse primer shown in SEQ ID NO.11, and the probe shown in SEQ ID NO.12; or,

[0026] The forward primer shown in SEQ ID NO.13, the reverse primer shown in SEQ ID NO.14, and the probe shown in SEQ ID NO.15.

[0027] In some embodiments of the present application, the primer pair and probe for detecting the PENK gene include:

[0028] The forward primer shown in SEQ ID NO.16, the reverse primer shown in SEQ ID NO.17, and the probe shown in SEQ ID NO.18; or,

[0029] The forward primer shown in SEQ ID NO.19, the reverse primer shown in SEQ ID NO.20, and the probe shown in SEQ ID NO.21; or,

[0030] The forward primer shown in SEQ ID NO.22, the reverse primer shown in SEQ ID NO.23, and the probe shown in SEQ ID NO.24; or,

[0031] The forward primer shown in SEQ ID NO.25, the reverse primer shown in SEQ ID NO.26, and the probe shown in SEQ ID NO.27; or,

[0032] The forward primer shown in SEQ ID NO.28, the reverse primer shown in SEQ ID NO.29, and the probe shown in SEQ ID NO.30.

[0033] In some embodiments of the present application, the primer pair and probe for detecting the NID2 gene include:

[0034] The forward primer shown in SEQ ID NO.31, the reverse primer shown in SEQ ID NO.32, and the probe shown in SEQ ID NO.33; or,

[0035] The forward primer shown in SEQ ID NO.34, the reverse primer shown in SEQ ID NO.35, and the probe shown in SEQ ID NO.36.

[0036] In some embodiments of the present application, the primer pair and probe for detecting biomarkers are composed of the primer pair and probe for detecting the TWIST1 gene and the primer pair and probe for detecting the PENK gene, or, are composed of the primer pair and probe for detecting the TWIST1 gene and the primer pair and probe for detecting the NID2 gene.

[0037] In some embodiments of the present application, in the primer pairs and probes for detecting biomarkers, the 5' end of the probe is labeled with a fluorescent group, and the 3' end is labeled with a quenching group; optionally, the excitation light waves of the fluorescent groups of the probes for detecting different biomarkers are different.

[0038] In some embodiments of the present application, the nucleic acid combination product further comprises a primer pair and a probe for detecting an internal reference gene;

[0039] Optionally, the primer pair and probe for detecting the internal reference gene include the forward primer shown in SEQ ID NO.37, the reverse primer shown in SEQ ID NO.38, and the probe shown in SEQ ID NO.39;

[0040] Further optionally, in the primer pair and probe for detecting the internal reference gene, the 5' end of the probe is labeled with a fluorescent group, and the 3' end is labeled with a quenching group;

[0041] Furthermore, the probe in the primer pair and probe for detecting the internal reference gene and the probe in the primer pair and probe for detecting the biomarker have fluorescent groups with different excitation light waves.

[0042] Yet another one or more embodiments of the present application provide a use of the nucleic acid combination product in the preparation of a bladder cancer diagnostic kit or a urothelial carcinoma diagnostic kit.

[0043] One or more embodiments of the present application also provide a kit comprising the nucleic acid combination product.

[0044] In some embodiments of the present application, the kit further comprises one or more of a DNA amplification reagent, a reagent for converting unmethylated cytosine bases into uracil, a DNA extraction reagent, and a DNA purification reagent.

[0045] The details of one or more embodiments of the present application are set forth in the description which follows, and other features, objects, and advantages of the present application will be apparent from the description and its claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0046] In order to more clearly illustrate the technical solutions in the embodiments of the present application and to more completely understand the present application and its beneficial effects, the following is a brief introduction to the drawings required for the description of the embodiments. Obviously, the drawings described below are only some embodiments of the present application, and those skilled in the art can obtain other drawings based on these drawings without creative work.

[0047] Figure 1 This is the ROC curve of the combined detection of TWIST1 gene and PENK gene;

[0048] Figure 2 This is the ROC curve of the combined detection of TWIST1 gene and NID2 gene;

[0049] Figure 3 is the test result corresponding to nucleic acid combination 1;

[0050] Figure 4 is the test result corresponding to nucleic acid combination 2;

[0051] Figure 5 is the test result corresponding to nucleic acid combination 3;

[0052] Figure 6 is the test result corresponding to nucleic acid combination 4;

[0053] Figure 7 is the test result corresponding to acid combination 5;

[0054] Figure 8 is the test result corresponding to nucleic acid combination 6;

[0055] Fig. 9 is the test result corresponding to nucleic acid combination 7;

[0056] Fig.10 is the test result corresponding to nucleic acid combination 8;

[0057] Fig.11 is the test result corresponding to nucleic acid combination 9;

[0058] Fig.12 is the test result corresponding to nucleic acid combination 10;

[0059] Fig.13 is the test result corresponding to nucleic acid combination 11;

[0060] Fig.14 is the test result corresponding to nucleic acid combination 12;

[0061] Fig.15 This is the result of the combined detection of nucleic acid combination 5 and nucleic acid combination 10;

[0062] Fig.16 This is the result of combined detection of TWIST1 and NID2. DETAILED DESCRIPTION

[0063] The present application will be further described in detail below in conjunction with the accompanying drawings, embodiments and examples. It should be understood that these embodiments and examples are only used to illustrate the present application and are not used to limit the scope of the present application. The purpose of providing these embodiments and examples is to make the understanding of the disclosure of the present application more thorough and comprehensive. It should also be understood that the present application can be implemented in many different forms, is not limited to the embodiments and examples described herein, and those skilled in the art can make various changes or modifications without violating the connotation of the present application, and the equivalent form obtained also falls within the protection scope of the present application. In addition, in the description below, a large number of specific details are given in order to provide a more comprehensive understanding of the present application, and it should be understood that the present application can be implemented without one or more of these details.

[0064] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this application belongs. The terms used herein in the specification of this application are only for the purpose of describing implementation modes and embodiments and are not intended to limit this application.

[0065] the term

[0066] Unless otherwise specified or incompatible herewith, the terms and phrases used herein shall have the following meanings:

[0067] The terms "and / or", "or / and", and "and / or" used in this article include any one of two or more related listed items, and also include any and all combinations of related listed items, and the arbitrary and all combinations include any two related listed items, any more related listed items, or a combination of all related listed items. It should be noted that when at least three items are connected by at least two conjunctions selected from "and / or", "or / and", and "and / or", it should be understood that in this application, the technical solution undoubtedly includes technical solutions that are all connected by "logical and", and undoubtedly includes technical solutions that are all connected by "logical or". For example, "A and / or B" includes three parallel solutions of A, B and A+B. For example, the technical solution of "A, and / or, B, and / or, C, and / or, D" includes any one of A, B, C, and D (that is, the technical solution that is all connected by "logical OR"), and also includes any and all combinations of A, B, C, and D, that is, the combination of any two or any three of A, B, C, and D, and also includes the combination of four of A, B, C, and D (that is, the technical solution that is all connected by "logical AND").

[0068] In the present application, "plurality", "multiple", "multiple times", "multiples", etc., unless otherwise specified, refer to a number greater than 2 or equal to 2. For example, "one or more" means one or greater than or equal to two.

[0069] As used herein, "combination thereof", "any combination thereof", "any combination thereof" etc. include all suitable combinations of any two or more of the listed items.

[0070] Herein, the “suitable” mentioned in “suitable combination”, “suitable method”, “any suitable method”, etc., shall be based on the ability to implement the technical solution of this application, solve the technical problems of this application, and achieve the expected technical effects of this application.

[0071] Herein, “preferred”, “better”, “more preferred” and “suitable” are merely used to describe implementation methods or examples with better effects, and it should be understood that they do not constitute limitations on the scope of protection of this application.

[0072] In the present application, "further", "further", "particularly" and the like are used for descriptive purposes to indicate differences in content, but should not be construed as limiting the scope of protection of the present application.

[0073] In this application, "optionally", "optional", and "optional" mean optional or dispensable, that is, any one of the two parallel schemes of "yes" or "no". If multiple "options" appear in a technical solution, unless otherwise specified and there is no contradiction or mutual restriction, each "optional" is independent.

[0074] In the present application, the terms "first", "second", "third", "fourth", etc. in "the first aspect", "the second aspect", "the third aspect", "the fourth aspect", etc. are used only for descriptive purposes and cannot be understood as indicating or implying relative importance or quantity, nor can they be understood as implicitly indicating the importance or quantity of the indicated technical features. Moreover, "first", "second", "third", "fourth", etc. only serve the purpose of non-exhaustive enumeration and description, and it should be understood that they do not constitute a closed limitation on quantity.

[0075] In the present application, the technical features described in an open manner include closed technical solutions composed of the listed features, and also include open technical solutions containing the listed features.

[0076] In the present application, when it comes to numerical intervals (i.e., numerical ranges), unless otherwise specified, the optional numerical distribution is considered continuous within the above numerical interval, and includes the two numerical endpoints (i.e., the minimum and maximum values) of the numerical range, and each numerical value between the two numerical endpoints. Unless otherwise specified, when the numerical interval only refers to the integers within the numerical interval, it includes the two endpoint integers of the numerical range, and each integer between the two endpoints. In this article, it is equivalent to directly listing each integer, such as t is an integer selected from 1 to 10, indicating that t is any integer selected from the group of integers consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10. In addition, when multiple ranges are provided to describe features or characteristics, these ranges can be combined. In other words, unless otherwise specified, the ranges disclosed herein should be understood to include any and all subranges included therein.

[0077] The temperature parameters in this application, unless otherwise specified, are allowed to be either constant temperature treatment or to vary within a certain temperature range. It should be understood that the constant temperature treatment allows the temperature to fluctuate within the accuracy range controlled by the instrument. Fluctuations within the range of ±5°C, ±4°C, ±3°C, ±2°C, and ±1°C are allowed.

[0078] In the present application, % (w / w) and wt% both represent weight percentage, % (v / v) refers to volume percentage, and % (w / v) refers to mass volume percentage.

[0079] All documents mentioned in this application are cited as references in this application, just as each document is cited as reference separately. Unless they conflict with the application purpose and / or technical solution of this application, the cited documents involved in this application are cited with all contents and all purposes. When the cited documents are involved in this application, the definitions of relevant technical features, terms, nouns, phrases, etc. in the cited documents are also cited. When the cited documents are involved in this application, the examples and preferred methods of the cited relevant technical features can also be incorporated into this application as references, but are limited to the implementation of this application. It should be understood that when the cited content conflicts with the description in this application, the present application shall prevail or be modified adaptively according to the description of this application.

[0080] In the reported literature, the sensitivity of single gene methylation detection for bladder cancer is 65%-100%. The clinical sensitivity of the same gene in different studies varies greatly. The factors to be considered are: ① Differences in the populations included in the study, which are affected by the disease spectrum of each research institution; ② Different studies tested the same gene, but the methylation sites in the promoter region were different; ③ Differences in the types of studies, retrospective and prospective studies, bring bias to the test results (Kim and Kim 2016). The traditionally reported genes used for bladder cancer detection, such as TWIST1, DAPK1, TERT, BCL2, p16, RASSF1A, COL1A2, have poor detection results.

[0081] Early detection of bladder cancer (BCa) provides favorable outcomes for patients and avoids the need for cystectomy. The development of accurate and sensitive non-invasive BCa diagnostic tests is imperative. DNA methylation is an early epigenetic event in the development of BCa. Certain specific abnormal methylation can serve as useful biomarkers. The purpose of this application is to identify methylation biomarkers for early detection of BCa. CpG methylation microarray analysis was performed on primary tumors and paired non-tumor tissues of different stages (T1-T4) from 9 BCa patients. Bisulfite pyrosequencing was performed to confirm the methylation status of candidate genes in tissues and urine sediments (n=51). Among them, PENK was selected as a potential candidate, and a set of independent 169 urine sediments (55BCa, 25 benign urological diseases, 8 other urological cancers, and 81 healthy controls) was used with quantitative methylation-specific real-time PCR (mePENK-qMSP). All statistical analyses were performed using MedCalc software version 9.3.2.0. CpG methylation microarray analysis and stepwise validation on tissue and urine sediments by bisulfite pyrosequencing supported aberrant methylation sites of the PENK gene as a potential biomarker for early detection of BCa. Clinical validation of the mePENK-qMSP test using urine sediment DNA showed a sensitivity of 86.5% (95% CI: 71.2-95.5%), a specificity of 92.5% (95% CI: 85.7-96.7%), and an area below the ROC of 0.920 (95% CI: 0.863-0.959) in detecting Ta high-grade and advanced tumor stages (T1-T4) in patients with BCa. The sensitivities were 55.6, 83.3, 88.5, and 100% for low-grade Ta, high-grade Ta, T1, and T2-T4, respectively. The methylation status of PENK was not associated with sex, age, or stage, but was associated with tumor grade of BCa. In this study, the present application analyzed the comprehensive pattern of DNA methylation and found that PENK methylation has high potential as a biomarker for early detection of BCa based on urine. The validation of PENK methylation confirmed that it can significantly improve the sensitivity and specificity of non-invasive detection of BCa. The kit provided by the present application can detect the methylation status of bladder cancer-related TWIST1, NID2, and PENK genes in urine exfoliated cells by methylation-specific real-time fluorescence PCR, which is an auxiliary diagnostic method for initial diagnosis of bladder cancer.

[0082] The term "diagnosis" includes auxiliary diagnosis, recurrence risk assessment, assessment of cancer risk and degree, and prognosis.

[0083] The term "oligonucleotide" or "polynucleotide" or "nucleotide" or "nucleic acid" refers to a molecule having two or more deoxyribonucleotides or ribonucleotides, preferably more than three, and usually more than ten. The exact size will depend on many factors, which in turn depend on the ultimate function or use of the oligonucleotide. Oligonucleotides can be produced in any manner, including chemical synthesis, DNA replication, reverse transcription, or a combination thereof. The typical deoxyribonucleotides of DNA are thymine, adenine, cytosine, and guanine. The typical ribonucleotides of RNA are uracil, adenine, cytosine, and guanine.

[0084] The term "methylation" is a form of chemical modification of DNA that can change genetic expression without changing the DNA sequence. DNA methylation refers to the covalent attachment of a methyl group to the 5th carbon position of cytosine in genomic CpG dinucleotides under the action of DNA methyltransferase. DNA methylation can cause changes in chromatin structure, DNA conformation, DNA stability, and the way DNA interacts with proteins, thereby controlling gene expression.

[0085] The term "methylation level" refers to whether cytosine in one or more CpG dinucleotides in a DNA sequence is methylated, or the frequency / ratio / percentage of methylation, which represents both a qualitative and a quantitative concept.

[0086] In practical applications, different detection indicators can be used to compare DNA methylation levels according to actual conditions. For example, in some cases, the comparison can be based on the Ct value of the sample test; in some cases, the proportion of gene methylation in the sample can be calculated, that is, the number of methylated molecules / (the number of methylated molecules + the number of unmethylated molecules) × 100, and then compared; in some cases, it is also necessary to statistically analyze and integrate various indicators to obtain the final judgment indicator.

[0087] The term "primer" refers to an oligonucleotide that can be used in an amplification method (e.g., polymerase chain reaction, PCR) to amplify a target sequence based on a polynucleotide sequence corresponding to a target gene or a portion thereof. Typically, at least one of the PCR primers used to amplify a polynucleotide sequence is sequence-specific for the polynucleotide sequence. The exact length of the primer depends on many factors, including temperature, primer source, and the method used. For example, for diagnostic and prognostic applications, oligonucleotide primers typically contain at least 10, 15, 20, 25 or more nucleotides, but may also contain fewer nucleotides, depending on the complexity of the target sequence. In the present disclosure, the term "primer" or "primer pair" refers to a pair of primers that can hybridize with the double-stranded DNA of a target DNA molecule or can hybridize with a region of a target DNA molecule that is located on both sides of the nucleotide sequence to be amplified.

[0088] The term "methylation-specific PCR" is one of the most sensitive experimental techniques for studying methylation, and can detect methylation in as little as about 50 pg of DNA. After single-stranded DNA is converted by bisulfite, all unmethylated cytosines are deaminated and converted to uracil, while methylated cytosines in CpG sites remain unchanged. Therefore, two pairs of primers are designed for methylated and unmethylated sequences respectively, and methylated and unmethylated DNA sequences can be distinguished through PCR amplification.

[0089] The term "methylation-specific fluorescent quantitative PCR (QMSP)" is an experimental technique that combines fluorescent quantitative PCR technology with methylation-specific PCR technology. This technology is also based on the sequence differences of DNA in different methylation states after bisulfite conversion to design appropriate primer pairs, thereby distinguishing methylated and unmethylated sequences, but the final detection indicator of q-MSP is a fluorescent signal. Therefore, in the q-MSP reaction system, in addition to adding methylation detection primers, fluorescent probes or fluorescent dyes are also required. Compared with traditional methylation-specific PCR technology, q-MSP has higher sensitivity and specificity in detecting DNA methylation levels, and is more suitable for detecting trace amounts of abnormally methylated DNA fragments mixed in the DNA of early cancer patients. This technology does not require gel electrophoresis detection and is easier to operate.

[0090] The term "probe" refers to an oligonucleotide sequence containing a 5' fluorescent group and a 3' quencher group. When the probe binds to the corresponding site on the DNA, the probe will not emit fluorescence because of the presence of a quencher group near the fluorescent group. During the amplification process, if the probe binds to the amplified chain, the 5'-3' exonuclease activity of the DNA polymerase (such as Taq enzyme) will digest the probe, and the fluorescent group will be away from the quencher group, and its energy will not be absorbed, thus generating a fluorescent signal. After each PCR cycle, the fluorescent signal also has a synchronous exponential growth process like the target fragment.

[0091] "Biomarker" or "biomarker" in this application refers to a substance such as a gene, a variable measurement related to a disease, which can serve as an indicator or predictor of that disease. The presence or risk of a disease can be inferred from the biomarker parameter without measuring the disease itself.

[0092] In a first aspect of an embodiment of the present application, a nucleic acid combination product is provided, which includes a primer pair and a probe for detecting a biomarker;

[0093] The primer pairs and probes for detecting biomarkers include: primer pairs and probes for detecting TWIST1 gene, and primer pairs and probes for detecting one or more of PENK gene and NID2 gene;

[0094] The primer pair and probe for detecting the TWIST1 gene include: a forward primer shown in any one of SEQ ID NO.1, SEQ ID NO.4, SEQ ID NO.7, SEQ ID NO.10 and SEQ ID NO.13, a reverse primer shown in any one of SEQ ID NO.2, SEQ ID NO.5, SEQ ID NO.8, SEQ ID NO.11 and SEQ ID NO.14, and a probe shown in any one of SEQ ID NO.3, SEQ ID NO.6, SEQ ID NO.9, SEQ ID NO.12 and SEQ ID NO.15;

[0095] The primer pair and probe for detecting the PENK gene include: a forward primer shown in any one of SEQ ID NO.16, SEQ ID NO.19, SEQ ID NO.22, SEQ ID NO.25 and SEQ ID NO.28, a reverse primer shown in any one of SEQ ID NO.17, SEQ ID NO.20, SEQ ID NO.23, SEQ ID NO.26 and SEQ ID NO.29, and a probe shown in any one of SEQ ID NO.18, SEQ ID NO.21, SEQ ID NO.24, SEQ ID NO.27 and SEQ ID NO.30;

[0096] The primer pair and probe for detecting the NID2 gene include: a forward primer shown in any one of SEQ ID NO.31 and SEQ ID NO.34, a reverse primer shown in any one of SEQ ID NO.32 and SEQ ID NO.35, and a probe shown in any one of SEQ ID NO.33 and SEQ ID NO.36.

[0097] In some of the examples, the primer pair and probe for detecting the TWIST1 gene include: a forward primer shown in SEQ ID NO.1, a reverse primer shown in SEQ ID NO.2, and a probe shown in SEQ ID NO.3; or, a forward primer shown in SEQ ID NO.4, a reverse primer shown in SEQ ID NO.5, and a probe shown in SEQ ID NO.6; or, a forward primer shown in SEQ ID NO.7, a reverse primer shown in SEQ ID NO.8, and a probe shown in SEQ ID NO.9; or, a forward primer shown in SEQ ID NO.10, a reverse primer shown in SEQ ID NO.11, and a probe shown in SEQ ID NO.12; or, a forward primer shown in SEQ ID NO.13, a reverse primer shown in SEQ ID NO.14, and a probe shown in SEQ ID NO.15.

[0098] In some of the examples, the primer pair and probe for detecting the PENK gene include: the forward primer shown in SEQ ID NO.16, the reverse primer shown in SEQ ID NO.17, and the probe shown in SEQ ID NO.18; or, the forward primer shown in SEQ ID NO.19, the reverse primer shown in SEQ ID NO.20, and the probe shown in SEQ ID NO.21; or, the forward primer shown in SEQ ID NO.22, the reverse primer shown in SEQ ID NO.23, and the probe shown in SEQ ID NO.24; or, the forward primer shown in SEQ ID NO.25, the reverse primer shown in SEQ ID NO.26, and the probe shown in SEQ ID NO.27; or, the forward primer shown in SEQ ID NO.28, the reverse primer shown in SEQ ID NO.29, and the probe shown in SEQ ID NO.30.

[0099] In some of the examples, the primer pair and probe for detecting the NID2 gene include: a forward primer shown in SEQ ID NO.31, a reverse primer shown in SEQ ID NO.32, and a probe shown in SEQ ID NO.33; or, a forward primer shown in SEQ ID NO.34, a reverse primer shown in SEQ ID NO.35, and a probe shown in SEQ ID NO.36.

[0100] In some examples, the primer pair and probe for detecting biomarkers are composed of the primer pair and probe for detecting TWIST1 gene and the primer pair and probe for detecting PENK gene. Optionally, the primer pair and probe for detecting biomarkers include nucleic acid combination 5 and nucleic acid combination 10, such as described in Example 1.

[0101] In some examples, the primer pair and probe for detecting biomarkers are composed of the primer pair and probe for detecting TWIST1 gene and the primer pair and probe for detecting NID2 gene. Optionally, the primer pair and probe for detecting biomarkers include nucleic acid combination 5 and nucleic acid combination 12, such as described in Example 2.

[0102] The present application does not particularly limit the method of using the nucleic acid combination product for detection. For example, the methylation level of the target region can be detected by one or more of the following methods: methylation-specific PCR method, bisulfite sequencing method, methylation-specific microarray method, whole genome bisulfite sequencing method, pyrophosphate sequencing method, methylation-specific high-performance liquid chromatography method, digital PCR method, methylation-specific high-resolution melting curve method, methylation-sensitive restriction endonuclease method and methylation-specific fluorescent quantitative PCR method.

[0103] In some examples, in the primer pairs and probes for detecting biomarkers, the 5' end of the probe is labeled with a fluorescent group, and the 3' end is labeled with a quenching group; optionally, the excitation light waves of the fluorescent groups of the probes for detecting different biomarkers are different.

[0104] In some examples, the nucleic acid combination product also includes a primer pair and a probe for detecting an internal reference gene;

[0105] Optionally, the primer pair and probe for detecting the internal reference gene include the forward primer shown in SEQ ID NO.37, the reverse primer shown in SEQ ID NO.38, and the probe shown in SEQ ID NO.39;

[0106] Further optionally, in the primer pair and probe for detecting the internal reference gene, the 5' end of the probe is labeled with a fluorescent group, and the 3' end is labeled with a quenching group;

[0107] Furthermore, the probe in the primer pair and probe for detecting the internal reference gene and the probe in the primer pair and probe for detecting the biomarker have fluorescent groups with different excitation light waves.

[0108] The second aspect of the embodiments of the present application provides a use of the nucleic acid combination product in the preparation of a bladder cancer diagnostic kit or a urothelial carcinoma diagnostic kit.

[0109] According to a third aspect of the embodiments of the present application, a kit is provided, which includes the nucleic acid combination product described above.

[0110] In some examples, the kit further comprises one or more of a DNA amplification reagent, a reagent for converting unmethylated cytosine bases into uracil, a DNA extraction reagent, and a DNA purification reagent.

[0111] The nucleic acid combination products and kits provided in this application are suitable for auxiliary diagnosis of patients who are clinically suspected of bladder cancer and are recommended to undergo cystoscopy due to hematuria, frequent urination, urgency and pain when urinating, and can be used as a supplement and aid to existing diagnostic methods for reference by clinical physicians.

[0112] The nucleic acid combination products and kits provided in this application are suitable for clinical auxiliary diagnosis of patients with suspected urothelial carcinoma who have low back pain, hematuria throughout the course, and blood clots in the form of strips. They can be used as a supplement and aid to existing diagnostic methods for reference by clinical physicians.

[0113] The nucleic acid combination and kit provided by the present application can be used for detecting urine samples as urine samples of the detection object. In the present application, "object" or "patient" or "subject" includes human patients and other mammals, and also includes any individual suffering from or suffering from bladder cancer, or any individual wishing to use the present application method for analysis or treatment. Suitable mammals falling within the scope of the present invention include but are not limited to: primates, livestock (e.g., sheep, cattle, horses, monkeys, pigs), laboratory test animals (e.g., rabbits, mice, rats, guinea pigs, hamsters), pets (e.g., cats, dogs) and captive wild animals (e.g., foxes, deer, dingoes). Preferably, the patient is a human patient.

[0114] The following are examples of nucleic acid combination products, kits, and methods for detecting urine samples using the nucleic acid combination products of the present application. It is understood that, in view of the general description provided above, various other embodiments can be implemented.

[0115] The embodiments of the present application will be described in detail below in conjunction with examples. It should be understood that these examples are only used to illustrate the present application and are not intended to limit the scope of the present application. The experimental methods for which specific conditions are not specified in the following examples are preferably referred to the guidance provided in the present application, and can also be based on the experimental manual or normal conditions in this area, can also be based on the conditions recommended by the manufacturer, or refer to experimental methods known in the art.

[0116] In the following specific embodiments, the measured parameters of raw material components may have slight deviations within the range of weighing accuracy unless otherwise specified. For temperature and time parameters, acceptable deviations caused by instrument test accuracy or operation accuracy are allowed.

[0117] Table 1. Primer pairs and probes for detecting TWIST1 gene

[0118]

[0119] Table 2. Primer pairs and probes for detecting PENK gene

[0120]

[0121] Table 3. Primer pairs and probes for detecting NID2 gene

[0122]

[0123] Table 4. Primer pairs and probes for detecting GAPDH gene

[0124]

[0125] In Tables 1 to 4, all primer sequences are from 5' to 3' end.

[0126] Example 1

[0127] 1. Sample selection

[0128] A total of 360 urine samples were selected, including 94 urine samples from bladder cancer patients, 114 urine samples from interference disease patients, and 152 urine samples from healthy people.

[0129] Sample inclusion criteria:

[0130] The following conditions were used for bladder cancer inclusion: The histological classification of bladder tumors was recommended to adopt the 2016 WHO Classification of Tumors of the Urinary System and Male Genital Organs (4th edition), which has some changes from the 2004 edition. The staging standard for bladder cancer was the 8th edition of the AJCC in 2017, based on the TNM staging system. Histopathological examination was used as the gold standard, and the final diagnosis was made by relying on the expertise of senior clinicians.

[0131] Interference samples were included in the group: patients with confirmed prostatic hyperplasia, bladder stones, urothelial infection and other diseases, and negative pathological results excluded bladder cancer.

[0132] The healthy group was selected under three conditions: (1) according to the questionnaire, subjects with common chronic diseases (hypertension, diabetes, coronary heart disease), tumor treatment history and major surgery history were excluded; (2) self-reported no obvious clinical symptoms; (3) physical examination results were within the normal range and no obvious abnormalities were found; and the examination results were beyond the normal range or abnormal but judged by the doctor to have no clinical significance. (The physical examination items include: LDCT, abdominal color Doppler ultrasound, 4 tumor markers, blood pressure, etc., as shown in the figure).

[0133] Exclusion criteria: under 18 years old; pregnant; duplicate samples, undiagnosed, or unqualified quality inspection.

[0134] 2. DNA Extraction

[0135] Using Quick-DNA TM Urine Kit Catalog No. D3061 (ZYMO RESEARCH) Easily purify cellular DNA / cell-free DNA from up to 40 mL of urine. DNA yield - The DNA binding capacity of the column is 5 μg.

[0136] Please note that DNA yields may vary depending on the urine itself. Female urine generally yields more DNA than male urine. The average range of urine DNA amounts for healthy female individuals is 6ng / mL-1000ng / mL. The average range for healthy male individuals is 2-20ng / mL.

[0137] 3. Methylation detection

[0138] The extracted and purified DNA / cell-free DNA was treated with bisulfite and purified and recovered using the ZYMO Methylation Kit D5005. The specific steps were referred to the instructions of the kit. 20 μL of Bis-DNA was finally obtained for each urine sample.

[0139] Using Bis-DNA as a template, the PCR reaction system of TWIST1, PENK and internal reference gene GAPDH was prepared with reference to Table 5. The primer pairs and probes used were nucleic acid combination 5 in Table 1 (TWIST1-F5: SEQ ID NO.13; TWIST1-R5: SEQ ID NO.14; TWIST1-P5: SEQ ID NO.15), nucleic acid combination 10 in Table 2 (PENK-F4: SEQ ID NO.28; PENK-R4: SEQ ID NO.29; PENK-P4: SEQ ID NO.30), and nucleic acid combination 13 in Table 4.

[0140] Table 5. Reaction system

[0141] Element Dosage 2×qPCR Mix (including taq enzyme, reaction buffer, dNTP, etc.) 12.5μL Forward primer (10 μM) 0.5μL Reaction primer (10 μM) 0.5μL Probe (10 μM) 0.5μL Nuclease-free water 6μL Bis-DNA (amplification template, concentration 0.2ng / μL) 5.0μL Total volume 25μL

[0142] Table 6. Reaction conditions and instruments

[0143]

[0144] Standard reference: positive control is bladder cancer tissue DNA; negative control is leukocyte DNA. The reaction system and reaction conditions of the corresponding controls are carried out according to Table 5 and Table 6.

[0145] 4. Judgment basis

[0146] The Ct values ​​of the reference gene, TWIST1 gene, and PENK gene were expressed as Ct0, Ct1, and Ct2, respectively, ΔCt1 = |Ct1-Ct0|, ΔCt2 = |Ct2-Ct0|, and a Ct0 value greater than 35 was considered unqualified. The result was determined under the condition that the Ct0 value was ≤35.

[0147] Table 7. Judgment basis for combined detection of TWIST1 gene and PENK gene

[0148]

[0149] Under the condition of single PENK gene testing, the following judgment criteria are used: Ct2≤35 and ΔCt2<8, it is judged as positive; other situations are judged as negative.

[0150] Table 8. Experimental results of combined detection of TWIST1 gene and PENK gene

[0151]

[0152] Sensitivity is the proportion of samples with positive methylation test results among samples with positive pathological results; specificity is the proportion of samples with negative methylation test results among samples with negative pathological results; accuracy is the proportion of samples with positive test results among samples. Figure 1 .

[0153] Example 2

[0154] An example of combined use of the TWIST1 gene and the NID2 gene.

[0155] 1. Sample selection is the same as in Example 1.

[0156] 2. DNA extraction is the same as in Example 1.

[0157] 3. The methylation detection is basically the same as in Example 1, except that the nucleic acid combination 5 in Table 1, the nucleic acid combination 13 in Table 4 and the nucleic acid combination 12 in Table 3 (NID2-F2: SEQ ID NO.34, NID2-R2: SEQID NO.35, NID2-P2: SEQ ID NO.36) are used in combination.

[0158] 4. Judgment basis

[0159] The Ct values ​​of the internal reference gene, TWIST1 gene, and NID2 gene were expressed as Ct0, Ct1, and Ct3, respectively, ΔCt1 = |Ct1-Ct0|, ΔCt3 = |Ct3-Ct0|, and a Ct0 value greater than 35 was considered unqualified. The result was determined under the condition that the Ct0 value was ≤35.

[0160] (1) The judgment basis for single TWIST1 is: if Ct1≤35, it is judged as positive; otherwise, it is judged as negative.

[0161] (2) The judgment basis for single NID2 is: if Ct3≤35, it is judged as positive; otherwise, it is judged as negative.

[0162] (3) The basis for the combined detection of TWIST1 and NID2:

[0163] 1) Ct1≤35, it can be judged as positive without determining NID2;

[0164] 2) 35<Ct1≤40, Ct3≤35 and △Ct3<8, it can be judged as positive;

[0165] Cases other than 1) and 2) are considered negative.

[0166] 5. Results

[0167] Table 9. Experimental results of combined detection of TWIST1 gene and NID2 gene

[0168] Single TWIST1 Single NID2 TWIST1、NID2 combination Among 94 patients 28 negative 46 negative 10 negative 114 Interference 0 positive 4 positive 12 positive 152 healthy people 4 positive 2 positive 4 positive

[0169] The results in the table show that the sensitivity of TWIST1 detection alone is 70.21%, the specificity is 98.496%, and the accuracy is 91.11%; the sensitivity of NID2 detection alone is 51.06%, the specificity is 97.74%, and the accuracy is 85.56%; the sensitivity of TWIST1 and NID2 combined detection is 89.36%, the specificity is 93.98%, and the accuracy is 92.78%. ROC curve is shown in Figure 2 .

[0170] Example 3

[0171] This embodiment is a blind test example, with a total of 220 urine samples. The pathological conditions of the urine samples are unknown (the hospital knows the pathological conditions). The test results are submitted to the hospital, and the hospital then provides feedback on the compliance rate of the experimental results.

[0172] The experiment was carried out in the same manner as in Example 1, and the final determination results are shown in Table 10.

[0173] Among the 220 samples: 74 out of 78 positive samples were detected as positive and 4 were negative; 4 out of 70 interference samples were detected as positive; 2 out of 72 healthy samples were detected as positive.

[0174] Table 10

[0175]

[0176] Referring to the reaction system described in Table 5 of Example 1, the reaction conditions and instruments described in Table 6, the positive control (bladder cancer tissue DNA) was tested using the nucleic acid composition in Table 1. The results are shown in Table 1. Figure 3 (corresponding to nucleic acid combination 1 in Table 1), Figure 4 (corresponding to nucleic acid combination 2 in Table 1), Figure 5 (corresponding to nucleic acid combination 3 in Table 1), Figure 6 (corresponding to nucleic acid combination 4 in Table 1), Figure 7 (Corresponding to nucleic acid combination 5 in Table 1) According to the test results, it can be seen that the nucleic acid combination 5 in Table 1 has the best effect.

[0177] Referring to the reaction system described in Table 5 of Example 1, the reaction conditions and instruments described in Table 6, the positive control (bladder cancer tissue DNA) was tested using the nucleic acid composition in Table 2. The results are shown in FIG. Figure 8 (corresponding to nucleic acid combination 6 in Table 2), Fig. 9 (corresponding to nucleic acid combination 7 in Table 2), Fig.10 (corresponding to nucleic acid combination 8 in Table 2), Fig.11 (corresponding to nucleic acid combination 9 in Table 2), Fig.12 (Corresponding to nucleic acid combination 10 in Table 2) According to the test results, it can be seen that the nucleic acid combination 10 in Table 2 has the best effect.

[0178] Referring to the reaction system described in Table 5 of Example 1, the reaction conditions and instruments described in Table 6, the positive control (bladder cancer tissue DNA) was tested using the nucleic acid composition in Table 3. The results are shown in Table 5. Fig.13 (corresponding to nucleic acid combination 11 in Table 3), Fig.14 (Corresponding to nucleic acid combination 12 in Table 3) According to the test results, it can be seen that the nucleic acid combination 12 in Table 3 has the best effect.

[0179] Referring to the reaction system described in Table 5 of Example 1, the reaction conditions and instruments described in Table 6, nucleic acid combination 5 and nucleic acid combination 10 were used to detect the positive control (bladder cancer tissue DNA). The results are shown in FIG. Fig.15 , pink is the internal reference gene, blue is the PENK gene test result, and green is the TWIST1 gene test result. This is the result of the combined test of TWIST1 and PENK displayed on the same graph.

[0180] Referring to the reaction system recorded in Table 5 of Example 1, the reaction conditions and instruments recorded in Table 6, nucleic acid combination 5 and nucleic acid combination 12 were used to detect the positive control (bladder cancer tissue DNA). The results are shown in Fig.16 , pink is the internal reference gene, blue is the NID2 gene detection result, and green is the TWIST1 gene detection result. This is the result of the combined detection of TWIST1 and NID2 displayed on the same graph.

[0181] In general, the embodiments of the present application provide a nucleic acid combination product and kit for detecting the TWIST1 gene and jointly detecting at least one of the NID2 and PENK genes, thereby enabling efficient, sensitive, and highly specific diagnosis and detection of cancer in a non-invasive manner.

[0182] Example 4

[0183] 1. Sample selection

[0184] A total of 370 urine samples were selected, including 104 urine samples from urothelial carcinoma patients, 114 urine samples from interference disease patients, and 152 urine samples from healthy people.

[0185] Sample inclusion criteria:

[0186] The following conditions were selected for inclusion in the urothelial carcinoma group: patients with clinical or case-diagnosed urothelial carcinoma;

[0187] Interference sample inclusion group: subjects clinically diagnosed with benign urinary system diseases;

[0188] The healthy group was selected under three conditions: (1) according to the questionnaire, subjects with common chronic diseases (hypertension, diabetes, coronary heart disease), history of tumor treatment and major surgery were excluded; (2) self-reported no obvious clinical symptoms; (3) physical examination results were within the normal range and no obvious abnormalities were found; and (4) the examination results were outside the normal range or abnormal but judged by the doctor to have no clinical significance (physical examination items include: LDCT, abdominal color Doppler ultrasound, 4 tumor markers, blood pressure, etc., as shown in the figure).

[0189] Exclusion criteria: under 18 years old; pregnant; duplicate samples, undiagnosed, or unqualified quality inspection.

[0190] 2. DNA extraction is the same as in Example 1.

[0191] 3. Methylation detection is the same as in Example 1.

[0192] 4. The judgment basis is the same as that in Example 1.

[0193] 5. Test results

[0194] Table 11. Experimental results of urothelial carcinoma detection

[0195]

[0196] The technical features of the above-mentioned implementation modes and examples can be combined in any appropriate manner. To make the description concise, not all possible combinations of the technical features in the above-mentioned implementation modes and examples are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0197] The above-described embodiments only express several implementation methods of the present application, which is convenient for understanding the technical solution of the present application in detail, but it cannot be understood as a limitation on the scope of protection of the patent application. It should be pointed out that for ordinary technicians in this field, without departing from the concept of the present application, several deformations and improvements can be made, which all belong to the protection scope of the present application. In addition, it should be understood that after reading the above-mentioned teaching content of the present application, the technicians in this field can make various changes or modifications to the present application, and the equivalent forms obtained also fall within the protection scope of the present application. It should also be understood that the technical solutions obtained by the technicians in this field through logical analysis, reasoning or limited experiments on the basis of the technical solutions provided in the present application are all within the protection scope of the claims attached to the present application. Therefore, the protection scope of the patent of the present application shall be based on the content of the attached claims, and the description and drawings can be used to explain the content of the claims.

Claims

1. Nucleic acid combination products, which include primer pairs and probes for detecting biomarkers; The primer pairs and probes for detecting biomarkers include: The primer pair and probe for detecting the TWIST1 gene also include a primer pair and probe for detecting one or more of the PENK gene and the NID2 gene; The primer pair and probe for detecting the TWIST1 gene include: a forward primer shown in any one of SEQ ID NO.1, SEQ ID NO.4, SEQ ID NO.7, SEQ ID NO.10 and SEQ ID NO.13, a reverse primer shown in any one of SEQ ID NO.2, SEQ ID NO.5, SEQ ID NO.8, SEQ ID NO.11 and SEQ ID NO.14, and a probe shown in any one of SEQ ID NO.3, SEQ ID NO.6, SEQ ID NO.9, SEQ ID NO.12 and SEQ ID NO.15; The primer pair and probe for detecting the PENK gene include: a forward primer shown in any one of SEQ ID NO.16, SEQ ID NO.19, SEQ ID NO.22, SEQ ID NO.25 and SEQ ID NO.28, a reverse primer shown in any one of SEQ ID NO.17, SEQ ID NO.20, SEQ ID NO.23, SEQ ID NO.26 and SEQ ID NO.29, and a probe shown in any one of SEQ ID NO.18, SEQ ID NO.21, SEQ ID NO.24, SEQ ID NO.27 and SEQ ID NO.30; The primer pair and probe for detecting the NID2 gene include: a forward primer shown in any one of SEQ ID NO.31 and SEQ ID NO.34, a reverse primer shown in any one of SEQ ID NO.32 and SEQ ID NO.35, and a probe shown in any one of SEQ ID NO.33 and SEQ ID NO.

36.

2. The nucleic acid combination product according to claim 1, in, The primer pair and probe for detecting the TWIST1 gene include: The forward primer shown in SEQ ID NO.1, the reverse primer shown in SEQ ID NO.2, and the probe shown in SEQ ID NO.3; or, The forward primer shown in SEQ ID NO.4, the reverse primer shown in SEQ ID NO.5, and the probe shown in SEQ ID NO.6; or, The forward primer shown in SEQ ID NO.7, the reverse primer shown in SEQ ID NO.8, and the probe shown in SEQ ID NO.9; or, The forward primer shown in SEQ ID NO.10, the reverse primer shown in SEQ ID NO.11, and the probe shown in SEQ ID NO.12; or, The forward primer shown in SEQ ID NO.13, the reverse primer shown in SEQ ID NO.14, and the probe shown in SEQ ID NO.

15.

3. The nucleic acid combination product according to claim 1, in, The primer pair and probe for detecting the PENK gene include: The forward primer shown in SEQ ID NO.16, the reverse primer shown in SEQ ID NO.17, and the probe shown in SEQ ID NO.18; or, The forward primer shown in SEQ ID NO.19, the reverse primer shown in SEQ ID NO.20, and the probe shown in SEQ ID NO.21; or, The forward primer shown in SEQ ID NO.22, the reverse primer shown in SEQ ID NO.23, and the probe shown in SEQ ID NO.24; or, The forward primer shown in SEQ ID NO.25, the reverse primer shown in SEQ ID NO.26, and the probe shown in SEQ ID NO.27; or, The forward primer shown in SEQ ID NO.28, the reverse primer shown in SEQ ID NO.29, and the probe shown in SEQ ID NO.

30.

4. The nucleic acid combination product according to claim 1, in, The primer pair and probe for detecting the NID2 gene include: The forward primer shown in SEQ ID NO.31, the reverse primer shown in SEQ ID NO.32, and the probe shown in SEQ ID NO.33; or, The forward primer shown in SEQ ID NO.34, the reverse primer shown in SEQ ID NO.35, and the probe shown in SEQ ID NO.

36.

5. The nucleic acid combination product according to any one of claims 1 to 4, in, The primer pair and probe for detecting biomarkers are composed of the primer pair and probe for detecting TWIST1 gene and the primer pair and probe for detecting PENK gene, or, are composed of the primer pair and probe for detecting TWIST1 gene and the primer pair and probe for detecting NID2 gene.

6. The nucleic acid combination product according to any one of claims 1 to 4, in, In the primer pair and probe for detecting biomarkers, the 5' end of the probe is labeled with a fluorescent group, and the 3' end is labeled with a quenching group.

7. The nucleic acid combination product according to claim 6, in, The fluorescent groups of the probes for detecting different biomarkers have different excitation light waves.

8. The nucleic acid combination product according to any one of claims 1 to 4 and 7, further comprising a primer pair and a probe for detecting an internal reference gene.

9. The nucleic acid combination product according to claim 8, in, The primer pair and probe for detecting the internal reference gene include a forward primer shown in SEQ ID NO.37, a reverse primer shown in SEQ ID NO.38, and a probe shown in SEQ ID NO.

39.

10. The nucleic acid combination product according to claim 9, in, In the primer pair and probe for detecting the internal reference gene, the 5' end of the probe is labeled with a fluorescent group, and the 3' end is labeled with a quenching group.

11. The nucleic acid combination product according to claim 10, in, The probe in the primer pair and probe for detecting the internal reference gene and the probe in the primer pair and probe for detecting the biomarker have fluorescent groups with different excitation light waves.

12. Use of the nucleic acid combination product according to any one of claims 1 to 11 in the preparation of a bladder cancer diagnosis kit or a urothelial carcinoma diagnosis kit.

13. A kit comprising the nucleic acid combination product of any one of claims 1 to 11.

14. The kit according to claim 13, further comprising one or more of a DNA amplification reagent, a reagent for converting unmethylated cytosine bases into uracil, a DNA extraction reagent, and a DNA purification reagent.

Citation Information

Patent Citations

  • Novel gene diagnosis kit for bladder cancer and application of novel gene diagnosis kit

    CN110283914A

  • Bladder cancer maker set and application thereof

    CN110343762A

  • Auxiliary diagnose method, reagent kit and system of bladder cancer through union of drive gene point mutation and methylation, and application

    CN110628910A

  • Primer, probe and kit for early screening and auxiliary diagnosis of bladder cancer

    CN111826446A

  • Composition for detecting bladder cancer and kit and application thereof

    CN113943799A